GASTROINTESTINAL COMPLICATIONS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID): EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS

Sterzel A\(^1\), Grass U\(^2\), Berger K\(^3\), Ple斯nila-Frank C\(^3\)
\(^1\)Altana Pharma AG, Konstanz, Germany, \(^2\)Altana Pharma Deutschland GmbH, Konstanz, Germany, \(^3\)MERG-Medical Economics Research Group, Munich, Germany

OBJECTIVES: To calculate the dimension of NSAID induced GI complications in Europe because few epidemiologic data exist. To find evidence of treatment patterns and analyse data on the economic burden of NSAID induced GI complications. To assess the economic benefit of ulcer prophylaxis with proton pump inhibitors (PPI). METHODS: Pub Med and Cochrane Library literature research was conducted with defined MESH terms. An epidemiological extrapolation was done to estimate hospitalisation and death cases due to NSAID use in Europe, limited to rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Economic benefit of ulcer prophylaxis was examined on the basis of international cost of illness and cost effectiveness studies.

RESULTS: Eighty-three studies were analysed. Approximately 3 million patients with RA and 17.3 million patients with OA were calculated for Europe. Potential incidence of hospitalisation due to NSAID use was 157933 patients annually with estimated 25222 cases of death. In the UK, total costs for inpatient stay and treatment of complications were about 367.5 million Euros per year. Data from The Netherlands showed that 14% of the costs of all GI complications were due to NSAID use. Across Europe, co-medication studies are rare; in France, co-medication was prescribed in 29.5%, in Spain in 41.6%, and in The Netherlands in 43% of NSAID users. Indirect costs (e.g. loss of productivity) ranged from 20–50% of total costs. CONCLUSION: Compared to our epidemiological extrapolation, much higher hospitalisation and death rates in Europe must be expected because of the wide range of NSAID indications. A lack of out-patient data limits a differentiated calculation of costs for NSAID induced complications. Although guidelines for ulcer prophylaxis do exist in many European countries, daily routine shows an inconsequent application of gastro protective agents. Given the calculated prevalences, prophylactic ulcer care with PPI should receive more attention in Europe.

ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE—FINAL RESULTS OF A CLINICAL COHORT TRIAL

Hessel FP
University of Duisburg-Essen, Essen, Germany

OBJECTIVES: Acute-on-chronic liver failure (ACLF) is a life threatening acute decompensation of a pre-existing chronic liver disease. The artificial liver support system MARS is a new emerging therapeutic option for treatment of ACLF. The medical efficacy of MARS has been demonstrated in first clinical studies. Objective of this study was to determine survival rates, quality of life, direct medical costs and cost-effectiveness. METHODS: In a clinical cohort trial with a prospective follow-up of 3 years and modelling of cost and survival for the remaining lifetime 62 consecutively included ACLF-patients treated with MARS were compared to 87 controls. Survival, health-related quality of life as well as direct medical costs for in- and outpatient treatment from a health care system perspective were determined and by bootstrapping the incremental costs per life year respectively QALY gained were estimated. RESULTS: There were no significant baseline differences between the two groups. Patients treated with MARS had a highly significant better survival (Logrank) with a mean outcome gain of 0.66 years, but bootstrap analysis showed broad confidence intervals (−0.12 to 1.46). The average initial intervention costs for MARS were €14,600 per patient treated. Incremental direct medical costs were €19,946 per patient treated with MARS (CI: 13,308 to 25,429). The mean costs per life-year gained were €29,985, costs per QALY were €43,040. In total, 34% of the bootstrap sample were higher than €50,000 per QALY. CONCLUSIONS: The results of the first economic evaluation study of MARS based on empirical patient data are presented. Although high initial treatment costs for MARS occur the significantly better survival led to reasonable costs per live year respectively QALY gained. But bootstrap analysis of CER showed a probability of 34% to be higher than 50,000€ per QALY gained. Further randomized controlled trials investigating the medical efficacy and the cost-effectiveness are recommended.

COMPARATIVE EFFICACY OF PARIET (RABEPROZOLE): LESSONS FROM CLAIMS DATA

Glass JR\(^1\), Rocchi A\(^2\), Lerorier J\(^3\)
\(^1\)Janssen-Ortho Inc,Toronto, ON, Canada, \(^2\)Axia Research, Hamilton, ON, Canada, \(^3\)Universite de Montreal, Montreal, QC, Canada

OBJECTIVES: Pariet (rabeprazole) was introduced at a substantial price discount to existing, branded proton pump inhibitors (PPIs) in Canada. Therefore, there may have been a perception of comparative reduced efficacy with Pariet, in part because Pariet is generally dosed at two tablets daily, compared to one unit daily for other PPIs. The objective was to conduct individual claims data descriptive analyses to identify differences in patterns of use indicative of reduced efficacy or selection of patients. METHODS: Individual claims data were obtained for Ontario, Canada. PPI claims were followed backward in time to determine if the patient had received a different PPI, an H2 antagonist or neither therapy previously (minimum time period, twelve months). This could suggest selection bias for naïve patients versus treatment-experienced patients. PPI claims were followed forward in time to determine if there were subsequent claims for a different PPI, an H2 antagonist, or neither. This proxy measure was interpreted as a lack of efficacy requiring therapy switches. RESULTS: Pariet users were equally likely as other PPI users to have had no claims for another PPI or H2 in the previous twelve months (74% PIP market overall, 70% Pariet). The proportion of patients who subsequently switched therapy increased as the duration of follow-up increased. Overall, Pariet users were most likely to have no subsequent claims for another PPI or an H2 antagonist compared to other PPIs (59% overall market, 71% Pariet users). CONCLUSION: Claims data do not support that Pariet has different efficacy from other PPIs or is used differently.

HEALTH-STATE UTILITIES IN LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

McLernon DJ, Dillon JF, Donnan PT
University of Dundee, Dundee, UK

OBJECTIVES: Health-state utilities are essential for cost-effectiveness analysis, and few estimates exist for liver disease in the literature. Our aim was to conduct a systematic review of health-state utilities in liver disease, and to estimate utilities for various liver disease states for a large UK Department of Health study. METHODS: Articles were included in the systematic review if health-state utility tools were used to estimate utility or if they